NASDAQ: SNDX Syndax Pharmaceuticals Inc 8-K

Syndax raises $243M from convertible debt offering, up to 13.6M shares at risk of dilution

Filed June 10, 2026 · Period ending June 10, 2026 · ~1 min read

Key Changes

  • high

    Syndax issued $250M of 2.25% convertible senior notes due 2031, netting $243M after fees. Funds will support R&D, commercialization, and general corporate needs.

  • high

    Up to 13.6M new shares could be issued if noteholders convert their debt to equity at the initial rate of 54.5 shares per $1,000 of principal, representing potential dilution to current shareholders.

  • medium

    Notes were sold in a private placement to qualified investors using SEC registration exemptions, with U.S. Bank Trust serving as trustee under the indenture.

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.

Partner

Trade SNDX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 10, 2026 9:35 PM